Jupiter Asset Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.1M Buy
+1,070,232
New +$9.59M 0.05% 298
2026
Q1
Sell
-146,120
Closed -$982K 536
2025
Q4
$982K Buy
146,120
+45,512
+45% +$343K 0.01% 352
2025
Q3
$872K Sell
100,608
-779,802
-89% -$6.07M 0.01% 356
2025
Q2
$5.55M Buy
880,410
+582,858
+196% +$3.86M 0.05% 268
2025
Q1
$1.91M Buy
+297,552
New +$2.46M 0.02% 339
2024
Q1
Sell
-36,667
Closed -$176K 495
2023
Q4
$176K Hold
36,667
﹤0.01% 446
2023
Q3
$265K Hold
36,667
﹤0.01% 456
2023
Q2
$272K Hold
36,667
﹤0.01% 484
2023
Q1
$256K Hold
36,667
﹤0.01% 389
2022
Q4
$377K Buy
+36,667
New +$647K 0.01% 421

Other funds holding NVAX

Jupiter Asset Management's NVAX Position: Q2 2026 in Review

Jupiter Asset Management opened a new position in Novavax (NVAX) in Q2 2026: 1,070,232 shares worth $10.1M. The stake represents 0.05% of the portfolio and ranks #298 among its holdings. This is a return to the name: Jupiter Asset Management previously reported a position in NVAX as recently as Q4 2025.

Jupiter Asset Management first reported a position in NVAX in Q4 2022 and has held it in 10 quarters since. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Jupiter Asset Management held 1,070,232 shares of Novavax worth $10.1M as of Q2 2026.
  • Novavax was a new Jupiter Asset Management position in Q2 2026.
  • Novavax made up 0.05% of Jupiter Asset Management's portfolio in Q2 2026, its #298 holding.
  • Jupiter Asset Management first reported a position in Novavax in Q4 2022 and has held it in 10 quarters since.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.